(Q42609665)

3 November 2017

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma (English)

1 reference

3 November 2017

phase II clinical trial

0 references

author

Mattias Carlsten

2

1 reference

3 November 2017

23

Ola Landgren

1 reference

3 November 2017

11

Adriana Zingone

1 reference

3 November 2017

Maryalice Stetler-Stevenson

20

object named as

Maryalice Stetler-Stevenson

1 reference

3 November 2017

21

Jane Trepel

1 reference

3 November 2017

Neha Korde

1

1 reference

3 November 2017

Min-Jung Lee

3

1 reference

3 November 2017

Alex Minter

4

1 reference

3 November 2017

Esther Tan

5

1 reference

3 November 2017

Mary Kwok

6

1 reference

3 November 2017

Elisabet Manasanch

7

1 reference

3 November 2017

Manisha Bhutani

8

1 reference

3 November 2017

Nishant Tageja

9

1 reference

3 November 2017

Mark Roschewski

10

1 reference

3 November 2017

Rene Costello

12

1 reference

3 November 2017

Marcia Mulquin

13

1 reference

3 November 2017

Diamond Zuchlinski

14

1 reference

3 November 2017

Irina Maric

15

1 reference

3 November 2017

Katherine R Calvo

16

1 reference

3 November 2017

Raul Braylan

17

1 reference

3 November 2017

Prashant Tembhare

18

1 reference

3 November 2017

Constance Yuan

19

1 reference

3 November 2017

Richard Childs

22

1 reference

3 November 2017

21 March 2014

1 reference

3 November 2017

1 reference

3 November 2017

99

1 reference

3 November 2017

e81-3

1 reference

3 November 2017

6

1 reference

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma

3 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040899

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040899

The role of natural killer cells in immunity against multiple myeloma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040899

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040899

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040899

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040899

Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040899

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040899

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040899

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040899

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040899

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040899

Smoldering multiple myeloma: natural history and recognition of an evolving type

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24658821

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24658821

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3324/HAEMATOL.2013.103085

1 reference

3 November 2017

1 reference

3 November 2017

1 reference